Researchers have discovered gene mutations that identify which lung cancer patients will respond to the drug Gefitinib, marketed as Iressa, found to radically reduce tumours in 14 per cent of patients, according to a new study.

Researchers at the University of Sydney say they have damning evidence the Australian tobacco industry has used clever marketing strategies to get around the current government restrictions on advertising.